Shanghai Shen Lian Biomedical Corporation (SHA:688098)
8.81
-0.15 (-1.67%)
May 12, 2026, 3:00 PM CST
SHA:688098 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 72.77 | 122 | 146.21 | 44.98 | 52.74 | 44.21 |
Trading Asset Securities | 10.52 | 32.82 | 43.81 | 162.38 | 305.12 | 424.08 |
Cash & Short-Term Investments | 83.29 | 154.82 | 190.02 | 207.35 | 357.87 | 468.29 |
Cash Growth | -41.01% | -18.52% | -8.36% | -42.06% | -23.58% | -20.23% |
Accounts Receivable | 296.16 | 282.11 | 261.4 | 273.97 | 222.76 | 154.61 |
Other Receivables | 3.31 | 3.33 | 3.17 | 3.09 | 6.82 | 5.99 |
Receivables | 299.47 | 285.44 | 264.57 | 277.06 | 229.57 | 160.61 |
Inventory | 109.45 | 94.47 | 95.1 | 111.79 | 115.33 | 103.42 |
Other Current Assets | 2.94 | 1.17 | 1.14 | 2.09 | 2.74 | 1.14 |
Total Current Assets | 495.15 | 535.9 | 550.83 | 598.29 | 705.5 | 733.46 |
Property, Plant & Equipment | 784.22 | 799.83 | 811.19 | 823.31 | 776.66 | 768.55 |
Long-Term Investments | 71.46 | 26.46 | 6.58 | 1.59 | 1.58 | 1.57 |
Other Intangible Assets | 122.12 | 124.7 | 102.66 | 93.6 | 53.12 | 32.66 |
Long-Term Deferred Tax Assets | 14.91 | 14.47 | 13.26 | 5.14 | 6.5 | 7.08 |
Long-Term Deferred Charges | 16.28 | 15.4 | 33.18 | 42.35 | 42.17 | 35.52 |
Other Long-Term Assets | 25.81 | 25.62 | 36.41 | 29.72 | 19.56 | 19.62 |
Total Assets | 1,530 | 1,542 | 1,554 | 1,594 | 1,605 | 1,598 |
Accounts Payable | 20.34 | 16.43 | 5.44 | 5.14 | 8.86 | 11.33 |
Accrued Expenses | 6.94 | 13.87 | 57.82 | 42.8 | 48.37 | 58.72 |
Short-Term Debt | 12.89 | 12.89 | 14.01 | - | - | - |
Current Portion of Long-Term Debt | 0.36 | 0.37 | - | - | - | - |
Current Portion of Leases | - | - | 0.48 | 0.33 | 0.14 | 0.13 |
Current Income Taxes Payable | 5.14 | 1.48 | - | 0.23 | 7.58 | 5.09 |
Current Unearned Revenue | 7.35 | 17.82 | 19.59 | 6.65 | 10.61 | 8.92 |
Other Current Liabilities | 70.83 | 70.47 | 18.86 | 21.35 | 21.66 | 29.33 |
Total Current Liabilities | 123.85 | 133.33 | 116.2 | 76.5 | 97.22 | 113.53 |
Long-Term Leases | 0.84 | 0.92 | 1.01 | 0.92 | 0.31 | 0.38 |
Long-Term Unearned Revenue | 8.61 | 9.11 | 11.08 | 9.49 | 10.36 | 11.3 |
Long-Term Deferred Tax Liabilities | 0.03 | 0.06 | 0.21 | 0.02 | 0.32 | 0.27 |
Total Liabilities | 133.33 | 143.41 | 128.5 | 86.93 | 108.21 | 125.48 |
Common Stock | 410.64 | 410.64 | 410.64 | 410.64 | 410.64 | 410.64 |
Additional Paid-In Capital | 539.23 | 539.23 | 539.23 | 539.23 | 546.04 | 552.18 |
Retained Earnings | 457.52 | 459.25 | 479.74 | 538.85 | 540.19 | 516.05 |
Treasury Stock | -20 | -20 | -18.32 | - | - | - |
Total Common Equity | 1,387 | 1,389 | 1,411 | 1,489 | 1,497 | 1,479 |
Minority Interest | 9.22 | 9.85 | 14.33 | 18.34 | - | -5.89 |
Shareholders' Equity | 1,397 | 1,399 | 1,426 | 1,507 | 1,497 | 1,473 |
Total Liabilities & Equity | 1,530 | 1,542 | 1,554 | 1,594 | 1,605 | 1,598 |
Total Debt | 14.09 | 14.17 | 15.49 | 1.25 | 0.45 | 0.51 |
Net Cash (Debt) | 69.2 | 140.65 | 174.53 | 206.1 | 357.42 | 467.78 |
Net Cash Growth | -44.70% | -19.41% | -15.32% | -42.34% | -23.59% | -20.32% |
Net Cash Per Share | - | 0.34 | 0.43 | 0.52 | 0.88 | 1.15 |
Filing Date Shares Outstanding | - | - | 407.53 | 410.64 | 410.64 | 379.56 |
Total Common Shares Outstanding | - | - | 407.53 | 410.64 | 410.64 | 379.56 |
Working Capital | 371.31 | 402.57 | 434.63 | 521.79 | 608.29 | 619.93 |
Book Value Per Share | - | - | 3.46 | 3.63 | 3.65 | 3.90 |
Tangible Book Value | 1,265 | 1,264 | 1,309 | 1,395 | 1,444 | 1,446 |
Tangible Book Value Per Share | - | - | 3.21 | 3.40 | 3.52 | 3.81 |
Buildings | - | - | 343.74 | 318.94 | 298.9 | 285.68 |
Machinery | - | - | 600.61 | 595.91 | 577.97 | 495.93 |
Construction In Progress | - | - | 177.87 | 163.44 | 98.95 | 133.78 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.